Full Name
Marie-Claire Peakman
Job Title
Partner
Company
Pfizer Ventures
Speaker Bio
Marie-Claire Peakman MRPharmS, PhD
Marie-Claire is a Partner on the Pfizer Ventures Team and an Executive Director in Worldwide Business Development at Pfizer. She is responsible for investing in early-stage biotech companies and supporting them in advancing emerging science to deliver new medicines to patients. Marie-Claire is on the Board of Directors for Curve Therapeutics, DEM Biopharma, Grey Wolf Therapeutics, Mozart Therapeutics, Normunity and Trimtech Therapeutics and holds observer positions on the boards of Mediar Therapeutics, Capstan Therapeutics, Crossbow Therapeutics and TRex Bio. She has 27 years of experience at Pfizer holding various leadership positions supporting small molecule discovery. As part of her former responsibilities, Marie-Claire founded and led the Primary Pharmacology Group for 13 years during which time they were responsible for the identification of nirmatrelvir (Paxlovid), abrocitinib (Cibinqo), ritlecitinib (Litfulo), and additional small molecule therapeutics that are currently in the clinic. She also has experience leading hit identification, high throughput ADME, compound management, data support and management, genetically modified models, preclinical imaging and biobanking.
Marie-Claire holds a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She conducted postdoctoral work at Yale University in the department of Molecular Biophysics & Biochemistry and the department of Molecular Psychiatry. She was recognized as a PhRMA ‘We Work For Health’ Champion in 2018. She is a member of The Royal Pharmaceutical Society, Immediate Past-Chair of the Board of Directors for United Way of Southeastern CT, and Chair of the Board of Trustees for Lawrence and Memorial Hospital.
Marie-Claire is a Partner on the Pfizer Ventures Team and an Executive Director in Worldwide Business Development at Pfizer. She is responsible for investing in early-stage biotech companies and supporting them in advancing emerging science to deliver new medicines to patients. Marie-Claire is on the Board of Directors for Curve Therapeutics, DEM Biopharma, Grey Wolf Therapeutics, Mozart Therapeutics, Normunity and Trimtech Therapeutics and holds observer positions on the boards of Mediar Therapeutics, Capstan Therapeutics, Crossbow Therapeutics and TRex Bio. She has 27 years of experience at Pfizer holding various leadership positions supporting small molecule discovery. As part of her former responsibilities, Marie-Claire founded and led the Primary Pharmacology Group for 13 years during which time they were responsible for the identification of nirmatrelvir (Paxlovid), abrocitinib (Cibinqo), ritlecitinib (Litfulo), and additional small molecule therapeutics that are currently in the clinic. She also has experience leading hit identification, high throughput ADME, compound management, data support and management, genetically modified models, preclinical imaging and biobanking.
Marie-Claire holds a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She conducted postdoctoral work at Yale University in the department of Molecular Biophysics & Biochemistry and the department of Molecular Psychiatry. She was recognized as a PhRMA ‘We Work For Health’ Champion in 2018. She is a member of The Royal Pharmaceutical Society, Immediate Past-Chair of the Board of Directors for United Way of Southeastern CT, and Chair of the Board of Trustees for Lawrence and Memorial Hospital.
Speaking At
